{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T07:02:25Z","timestamp":1793775745776,"version":"4.6.1"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Immune correlates of protection afforded by PHV02, a recombinant vesicular stomatitis (rVSV) vector vaccine against Nipah virus (NiV) disease, were investigated in the African green monkey (AGM) model. Neutralizing antibody to NiV has been proposed as the principal mediator of protection against future NiV infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Two approaches were used to determine the correlation between neutralizing antibody levels and outcomes following a severe (1,000 median lethal doses) intranasal\/intratracheal (IN\/IT) challenge with NiV (Bangladesh): (1) reduction in vaccine dose given 28 days before challenge and (2) challenge during the early phase of the antibody response to the vaccine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Reduction in vaccine dose to very low levels led to primary vaccine failure rather than a sub-protective level of antibody. All AGMs vaccinated with the nominal clinical dose (2 \u00d7 10\n                      <jats:sup>7<\/jats:sup>\n                      pfu) at 21, 14, or 7 days before challenge survived. AGMs vaccinated at 21 days before challenge had neutralizing antibodies (geometric mean titer, 71.3). AGMs vaccinated at 7 or 14 days before challenge had either undetectable or low neutralizing antibody titers pre-challenge but had a rapid rise in titers after challenge that abrogated the NiV infection. A simple logistic regression model of the combined studies was used, in which the sole explanatory variable was pre-challenge neutralizing antibody titers. For a pre-challenge titer of 1:5, the predicted survival probability is 100%. The majority of animals with pre-challenge neutralizing titer of \u22651:20 were protected against pulmonary infiltrates on thoracic radiograms, and a majority of those with titers \u22651:40 were protected against clinical signs of illness and against a \u2265fourfold antibody increase following challenge (indicating sterile immunity). Controls receiving rVSV-Ebola vaccine rapidly succumbed to NiV challenge, eliminating the innate immunity stimulated by the rVSV vector as a contributor to survival in monkeys challenged as early as 7 days after vaccination.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion and conclusion<\/jats:title>\n                    <jats:p>It was concluded that PHV02 vaccine elicited a rapid onset of protection and that any detectable level of neutralizing antibody was a functional immune correlate of survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2023.1216225","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:17:15Z","timestamp":1693804635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Immunological correlates of protection afforded by PHV02 live, attenuated recombinant vesicular stomatitis virus vector vaccine against Nipah virus disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Thomas P.","family":"Monath","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Nichols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friederike","family":"Feldmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Haddock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Callison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Meade-White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Okumura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lovaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick W.","family":"Hanley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chad S.","family":"Clancy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl","family":"Shaia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasima","family":"Rida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Fusco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-323-35761-6.00002-X","article-title":"Vaccine immunology","volume-title":"Plotkin\u2019s vaccines","author":"Siegrist","year":"2018"},{"key":"B2","article-title":"Immune correlates","volume-title":"Plotkin\u2019s vaccines","author":"Plotkin","year":"2018"},{"key":"B3","volume-title":"Guidance for industry expedited programs for serious conditions \u2013 drugs and biologics","year":"2020"},{"key":"B4","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1038\/s41541-020-00261-9","article-title":"Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate","volume":"5","author":"Roozendaal","year":"2020","journal-title":"NPJ Vaccines"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"Khoury","year":"2021","journal-title":"Nat Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268819000086","article-title":"Nipah virus infection: A review","volume":"147","author":"Aditi","year":"2019","journal-title":"Epidemiol Infect"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/ana.10212","article-title":"Relapsed and late-onset Nipah encephalitis","volume":"51","author":"Tan","year":"2002","journal-title":"Ann Neurol"},{"key":"B8","unstructured":"R&D blueprint2015"},{"key":"B9","article-title":"Lessons from the Nipah virus outbreak in Malaysia","volume":"29","author":"Looi","year":"2007","journal-title":"Malays J Pathol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"101413","DOI":"10.1016\/j.smim.2020.101413","article-title":"Transforming vaccine development","volume":"50","author":"Black","year":"2020","journal-title":"Semin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00705-012-1352-5","article-title":"The immune response to Nipah virus infection","volume":"157","author":"Prescott","year":"2012","journal-title":"Arch Virol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1162","DOI":"10.3390\/microorganisms10061162","article-title":"The immunobiology of nipah virus","volume":"10","author":"Liew","year":"2022","journal-title":"Microorganisms"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2014.02.087","article-title":"Single-dose live-attenuated Nipah virus vaccines confer complete protection by eliciting antibodies directed against surface glycoproteins","volume":"32","author":"DeBuysscher","year":"2014","journal-title":"Vaccine"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000642","article-title":"A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection","volume":"5","author":"Bossart","year":"2009","journal-title":"PLoS Pathog"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1016\/j.cell.2020.11.023","article-title":"Potent henipavirus neutralization by antibodies recognizing diverse sites on hendra and nipah virus receptor binding protein","volume":"183","author":"Dong","year":"2020","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"109628","DOI":"10.1016\/j.celrep.2021.109628","article-title":"Cooperativity mediated by rationally selected combinations of human monoclonal antibodies targeting the henipavirus receptor binding protein","volume":"36","author":"Doyle","year":"2021","journal-title":"Cell Rep"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41594-021-00584-8","article-title":"Broadly neutralizing antibody cocktails targeting Nipah virus and Hendra virus fusion glycoproteins","volume":"28","author":"Dang","year":"2021","journal-title":"Nat Struct Mol Biol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1080\/22221751.2019.1571871","article-title":"Nipah pseudovirus system enables evaluation of vaccines in vitro and in vivo using non-BSL-4 facilities","volume":"8","author":"Nie","year":"2019","journal-title":"Emerg Microbes Infect"},{"key":"B19","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1002\/path.4444","article-title":"Animal models of disease shed light on Nipah virus pathogenesis and transmission","volume":"235","author":"de Wit","year":"2015","journal-title":"J Pathol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.03.089","article-title":"Single-dose live-attenuated vesicular stomatitis virus-based vaccine protects African green monkeys from Nipah virus disease","volume":"33","author":"Prescott","year":"2015","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"30916","DOI":"10.1038\/srep30916","article-title":"Pathogenic differences between nipah virus Bangladesh and Malaysia strains in primates: Implications for antibody therapy","volume":"6","author":"Mire","year":"2016","journal-title":"Sci Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz613","article-title":"Resistance of cynomolgus monkeys to nipah and hendra virus disease is associated with cell-mediated and humoral immunity","volume":"221","author":"Prasad","year":"2020","journal-title":"J Infect Dis"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1086\/529147","article-title":"Clinical presentation of nipah virus infection in Bangladesh","volume":"46","author":"Hossain","year":"2008","journal-title":"Clin Infect Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100001785","article-title":"Nipah encephalitis outbreak in Malaysia, clinical features in patients from Seremban","volume":"29","author":"Chong","year":"2002","journal-title":"Can J Neurol Sci"},{"key":"B25","article-title":"Nipah virus infection in kozhikode, kerala, south India, in 2018: Epidemiology of an outbreak of an emerging disease","volume":"44","author":"Thomas","year":"2019","journal-title":"Indian J Community Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.3201\/eid1307.061128","article-title":"Person-to-person transmission of Nipah virus in a Bangladeshi community","volume":"13","author":"Gurley","year":"2007","journal-title":"Emerg Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0005532","article-title":"Loss in lung volume and changes in the immune response demonstrate disease progression in African green monkeys infected by small-particle aerosol and intratracheal exposure to Nipah virus","volume":"11","author":"Cong","year":"2017","journal-title":"PLoS Negl Trop Dis"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00473-11","article-title":"Clinical outcome of henipavirus infection in hamsters is determined by the route and dose of infection","volume":"85","author":"Rockx","year":"2011","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30313-4","article-title":"Safety and immunogenicity of the rVSV\u0394G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study","volume":"17","author":"Heppner","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj1701","article-title":"A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa","volume":"9","author":"Huttner","year":"2017","journal-title":"Sci Transl Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.774026","article-title":"Single dose of a VSV-based vaccine rapidly protects macaques from marburg virus disease","volume":"12","author":"Marzi","year":"2021","journal-title":"Front Immunol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw218","article-title":"Efficacy of vesicular stomatitis virus-ebola virus postexposure treatment in rhesus macaques infected with ebola virus makona","volume":"214","author":"Marzi","year":"2016","journal-title":"J Infect Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"16002\u2013","DOI":"10.1038\/npjvaccines.2016.2","article-title":"Peri-exposure protection against Nipah virus disease using a single-dose recombinant vesicular stomatitis virus-based vaccine","volume":"1","author":"DeBuysscher","year":"2016","journal-title":"NPJ Vaccines"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.129629","article-title":"Nipah virus persists in the brains of nonhuman primate survivors","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010658","article-title":"Recombinant vesicular stomatitis vaccine against Nipah virus has a favorable safety profile: Model for assessment of live vaccines with neurotropic potential","volume":"18","author":"Monath","year":"2022","journal-title":"PLoS Pathog"},{"key":"B37","article-title":"Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis)","volume":"60","author":"Brining","year":"2010","journal-title":"Comp Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1216225\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T05:17:20Z","timestamp":1693804640000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1216225\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2023.1216225"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1216225","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,4]]},"article-number":"1216225"}}